These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 17888143)

  • 1. Sulphonylurea treatment does not improve psychomotor development in children with KCNJ11 mutations causing permanent neonatal diabetes mellitus accompanied by developmental delay and epilepsy (DEND syndrome).
    Sumnik Z; Kolouskova S; Wales JK; Komarek V; Cinek O
    Diabet Med; 2007 Oct; 24(10):1176-8. PubMed ID: 17888143
    [No Abstract]   [Full Text] [Related]  

  • 2. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain.
    Shimomura K; Hörster F; de Wet H; Flanagan SE; Ellard S; Hattersley AT; Wolf NI; Ashcroft F; Ebinger F
    Neurology; 2007 Sep; 69(13):1342-9. PubMed ID: 17652641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features.
    Gloyn AL; Diatloff-Zito C; Edghill EL; Bellanné-Chantelot C; Nivot S; Coutant R; Ellard S; Hattersley AT; Robert JJ
    Eur J Hum Genet; 2006 Jul; 14(7):824-30. PubMed ID: 16670688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.
    Mlynarski W; Tarasov AI; Gach A; Girard CA; Pietrzak I; Zubcevic L; Kusmierek J; Klupa T; Malecki MT; Ashcroft FM
    Nat Clin Pract Neurol; 2007 Nov; 3(11):640-5. PubMed ID: 17982434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM.
    Mohamadi A; Clark LM; Lipkin PH; Mahone EM; Wodka EL; Plotnick LP
    Pediatr Diabetes; 2010 May; 11(3):203-7. PubMed ID: 19686306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.
    Gloyn AL; Pearson ER; Antcliff JF; Proks P; Bruining GJ; Slingerland AS; Howard N; Srinivasan S; Silva JM; Molnes J; Edghill EL; Frayling TM; Temple IK; Mackay D; Shield JP; Sumnik Z; van Rhijn A; Wales JK; Clark P; Gorman S; Aisenberg J; Ellard S; Njølstad PR; Ashcroft FM; Hattersley AT
    N Engl J Med; 2004 Apr; 350(18):1838-49. PubMed ID: 15115830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation.
    Slingerland AS; Hurkx W; Noordam K; Flanagan SE; Jukema JW; Meiners LC; Bruining GJ; Hattersley AT; Hadders-Algra M
    Diabet Med; 2008 Mar; 25(3):277-81. PubMed ID: 18307455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Permanent neonatal diabetes mellitus caused by a novel mutation in the KCNJ11 gene.
    Doneray H; Houghton J; Tekgunduz KS; Balkir F; Caner I
    J Pediatr Endocrinol Metab; 2014 Mar; 27(3-4):367-71. PubMed ID: 24150202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infantile spasms as an epileptic feature of DEND syndrome associated with an activating mutation in the potassium adenosine triphosphate (ATP) channel, Kir6.2.
    Bahi-Buisson N; Eisermann M; Nivot S; Bellanné-Chantelot C; Dulac O; Bach N; Plouin P; Chiron C; de Lonlay P
    J Child Neurol; 2007 Sep; 22(9):1147-50. PubMed ID: 17890419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.
    Slingerland AS; Nuboer R; Hadders-Algra M; Hattersley AT; Bruining GJ
    Diabetologia; 2006 Nov; 49(11):2559-63. PubMed ID: 17047922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfer to sulphonylurea therapy in adult subjects with permanent neonatal diabetes due to KCNJ11-activating [corrected] mutations: evidence for improvement in insulin sensitivity.
    Malecki MT; Skupien J; Klupa T; Wanic K; Mlynarski W; Gach A; Solecka I; Sieradzki J
    Diabetes Care; 2007 Jan; 30(1):147-9. PubMed ID: 17192350
    [No Abstract]   [Full Text] [Related]  

  • 12. Glibenclamide unresponsiveness in a Brazilian child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2) gene.
    Della Manna T; Battistim C; Radonsky V; Savoldelli RD; Damiani D; Kok F; Pearson ER; Ellard S; Hattersley AT; Reis AF
    Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1350-5. PubMed ID: 19169493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful transition to sulfonylurea therapy in two Iraqi siblings with neonatal diabetes mellitus and iDEND syndrome due to ABCC8 mutation.
    Ozsu E; Giri D; Seymen Karabulut G; Senniappan S
    J Pediatr Endocrinol Metab; 2016 Dec; 29(12):1403-1406. PubMed ID: 27849623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide.
    Bremer AA; Ranadive S; Lustig RH
    Pediatr Diabetes; 2008 Jun; 9(3 Pt 1):236-9. PubMed ID: 18221420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful transition to sulfonylurea in neonatal diabetes, developmental delay, and seizures (DEND syndrome) due to R50P KCNJ11 mutation.
    Peña-Almazan S
    Diabetes Res Clin Pract; 2015 Apr; 108(1):e18-20. PubMed ID: 25678012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DEND syndrome due to V59A mutation in KCNJ11 gene: unresponsive to sulfonylureas.
    Itoh S; Matsuoka H; Yasuda Y; Miyake N; Suzuki K; Yorifuji T; Sugihara S
    J Pediatr Endocrinol Metab; 2013; 26(1-2):143-6. PubMed ID: 23382304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First case of neonatal diabetes with KCNJ11 Q52R mutation successfully switched from insulin to sulphonylurea treatment.
    Ioacara S; Flanagan S; Fröhlich-Reiterer E; Goland R; Fica S
    J Diabetes Investig; 2017 Sep; 8(5):716-719. PubMed ID: 28083968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation.
    Ješić MM; Ješić MD; Maglajlić S; Sajić S; Necić S
    Diabetes Res Clin Pract; 2011 Jan; 91(1):e1-3. PubMed ID: 21056492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulfonylurea-responsive diabetes in childhood.
    Landau Z; Wainstein J; Hanukoglu A; Tuval M; Lavie J; Glaser B
    J Pediatr; 2007 May; 150(5):553-5. PubMed ID: 17452235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable phenotypic spectrum of diabetes mellitus in a family carrying a novel KCNJ11 gene mutation.
    D'Amato E; Tammaro P; Craig TJ; Tosi A; Giorgetti R; Lorini R; Ashcroft FM
    Diabet Med; 2008 Jun; 25(6):651-6. PubMed ID: 18544102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.